scholarly journals Comparison of the efficacy of long-term treatment of primary monosymptomatic nocturnal enuresis of varying severity using traditional methods

2018 ◽  
Vol 47 (3) ◽  
pp. 249
Author(s):  
Kirill Kosilov ◽  
Irina Kuzina ◽  
Vladimir Kuznetsov ◽  
Yuliya Gainullina ◽  
Liliya Kosilova ◽  
...  
Keyword(s):  
Nocturnal Enuresis ◽  
Term Treatment ◽  
Traditional Methods ◽  
Long Term Treatment ◽  
Monosymptomatic Nocturnal Enuresis ◽  
Primary Monosymptomatic Nocturnal Enuresis

Long-term treatment of nocturnal enuresis with desmopressin

1991 ◽  
Vol 19 (4) ◽  
pp. 237-240 ◽  
Author(s):  
U. B. Knudsen ◽  
S. Rittig ◽  
J. P. N�rgaard ◽  
J. B. Lundemose ◽  
E. B. Pedersen ◽  
...  
Keyword(s):  
Nocturnal Enuresis ◽  
Term Treatment ◽  
Long Term Treatment

Desmopressin Tablets in the Treatment of Severe Nocturnal Enuresis in Adolescents

PEDIATRICS ◽  
1994 ◽  
Vol 94 (6) ◽  
pp. 841-846
Author(s):  
Arne Stenberg ◽  
Göran Läckgren
Keyword(s):  
Nocturnal Enuresis ◽  
Term Treatment ◽  
Dose Titration ◽  
Optimal Dosage ◽  
Double Blind ◽  
Long Term Study ◽  
Titration Period ◽  
Long Term Treatment ◽  
Clinically Significant

Background. In recent years the treatment of primary nocturnal enuresis (PNE) with desmopressin (DDAVP) has been promising. The route of administration until now had been intranasal, but because the tablets were introduced for the treatment of diabetes insipidus they have also become available for the treatment of PNE. Objectives. To find the optimal dosage of desmopressin tablets and to compare desmopressin's efficacy with placebo in a group of adolescents with severe monosymptomatic enuresis. The long-term safety of desmopressin was also studied in the same group of patients. Methods. The effect of oral desmopressin (1-deamino-8-D-arginine-vasopressin) (DDAVP® tablets, Minirin®) was investigated in 25 adolescents (ages 11 to 21 years) with severe monosymptomatic nocturnal enuresis. The first part of the dose-ranging study comprised a single-blind dose titration period, followed by a double-blind, crossover efficacy period comparing desmopressin with placebo. The final part was an open long-term study consisting of two 12-week treatment periods. The efficacy of the drug was measured in reductions of the number of wet nights per week. Results. During the first dose-titration period, the majority of the patients were given desmopressin 400 µg, and the number of wet nights decreased from a mean of 4.9 to 2.8. During the double-blind period, a significant reduction of wet nights was observed (1.8 vs 4.1 for placebo). During the two long-term periods, 48% and 53% of the patients could be classified as responders (0 to 1 wet night per week) and 22% and 23.5% as intermediate responders (2 to 3 wet nights per week). No weight gain was observed due to water retention. After cessation of the drug, 44% of the patients had a significant decrease in the number of wet nights. Conclusions. Oral desmopressin has a clinically significant effect on patients with PNE, and therapy is safe when administered as long-term treatment.

Desmopressin in a long-term treatment of children with primary nocturnal enuresis – a symptomatic therapy?

2001 ◽  
Vol 160 (3) ◽  
pp. 197-198 ◽  
Author(s):  
Marta Šnajderová ◽  
Veronika Lehotská ◽  
Tatiana Kernová ◽  
Nadeˇje Kocˇnarová ◽  
Eva Archmanová ◽  
...  
Keyword(s):  
Nocturnal Enuresis ◽  
Term Treatment ◽  
Symptomatic Therapy ◽  
Primary Nocturnal Enuresis ◽  
Long Term Treatment

Hypnotherapy is effective in the long-term treatment of functional dyspepsia

2001 ◽  
Vol 120 (5) ◽  
pp. A115-A115 ◽  
Author(s):  
E CALVERT ◽  
L HOUGHTON ◽  
P COOPER ◽  
P WHORWELL
Keyword(s):  
Functional Dyspepsia ◽  
Term Treatment ◽  
Long Term Treatment
Sign in / Sign up

Export Citation Format

Share Document